Luminoma is commercialising a high-margin AI platform, the LumAssure™, that instantly and accurately diagnoses skin cancer at the point of care, directly monetising a multi-billion dollar inefficiency in dermatology clinics and patient convenience.
Value Proposition
Skin cancer screening involves assessing a mole’s appearance. Diagnosing skin cancers can be challenging and primarily relies on a clinician's judgement and expertise. Experienced clinicians will miss 1 in 8 cancers, whilst less experienced clinicians can miss up to half. So to avoid missing a cancer, clinicians can biopsy 3 to 30 lesions for every cancer found. These unnecessary biopsies not only waste time and money but can cause unsightly scarring.
Luminoma is developing the LumAssure, a non-invasive, point-and-click device that indicates whether a skin lesion is malignant or benign within seconds. The LumAssure will reduce missed cancers from 1 in 8 to less than 1 in 100 as well as reducing unnecessary biopsies by three quarters. The diagnostic-aid’s high accuracy provides clinicians with assurance in their biopsy decisions without having to wait days for a lab result.
Opportunity highlights
Significant market opportunity: We will first launch with premium dermatology clinics whose patients will want the convenience of an instant result whilst avoiding unnecessary procedures and scarring. We estimate the serviceable obtainable market in US dermatology to be a US$2B annual recurring revenue opportunity with additional revenue in primary care within integrated care systems.
Validated market excitement: Letters of intent and active development partnerships with top US hospitals and the largest dermatology practice in the US, de-risk commercial adoption.
Scalable skin analysis platform: The first application is skin cancer can be expanded to inflammatory diseases, e.g., psoriasis and eczema as well as skin aging, cosmetic cream performance and wound healing.
Proven team with serial exits: Founders have a demonstrated history of building, regulating, and exiting medical device and digital health companies (e.g., Engender → CRV; ResApp Health→ Pfizer) as well as implementing spectroscopic solutions for industry (Fonterra).
Investment terms: A funding round of $9 million is sought in mid-2026 at a pre-money valuation of $20 to $25 million.
Problem and Solution
Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.
Duis vitae mi neque. Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus tempor lectus lectus vel diam.
Proin neque lacus, semper vel ex at, eleifend rhoncus est.
Cras non nisi urna. Sed feugiat dignissim erat, eget convallis nisl blandit a.
Nullam fringilla diam eget dui placerat fermentum. Maecenas malesuada viverra leo eu bibendum. Nam vulputate enim velit, eu pretium justo tristique ac.
Nam vitae varius augue. Nam pharetra facilisis elementum. Sed nisl risus, vestibulum ut velit at, dapibus sagittis arcu.
Nullam sed dolor suscipit, efficitur enim quis, vestibulum sapien. Nunc convallis mauris nec nibh mollis, eget aliquet odio tincidunt.
Phasellus faucibus sem mauris, sed iaculis nisl egestas sed.
Sed sit amet gravida elit, sagittis sollicitudin nulla. Vivamus auctor arcu eu scelerisque convallis. Phasellus scelerisque ultrices tincidunt. Curabitur odio libero, faucibus et felis nec, pulvinar facilisis urna. In
Proin auctor bibendum ex, non condimentum tortor sodales vitae. Ut feugiat at lorem accumsan consequat.
Suspendisse ac condimentum ipsum, sit amet auctor dui. Aliquam pretium justo in commodo varius.
Pellentesque elementum felis non urna vulputate, non posuere metus suscipit.
Aenean lacinia id quam a lobortis. Cras nibh lorem, vulputate eget purus elementum, pharetra condimentum elit.
Quisque et sagittis ex, vitae ultrices nulla. Vivamus dapibus blandit libero, et scelerisque dui ullamcorper ut. Vivamus ut molestie ex. Integer eget tempus mauris. Quisque volutpat pulvinar urna, posuere pharetra ex auctor vel. Sed id lacus tortor. Proin nisl turpis, tempus a leo in, lacinia volutpat orci.
Aenean nulla nibh, porta a dignissim vitae, laoreet vitae lacus. Nunc in aliquet urna. Vivamus vel turpis a mi consequat venenatis. Pellentesque tincidunt ante ut urna accumsan lacinia. Sed
Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.
Duis vitae mi neque. Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus tempor lectus lectus vel diam.
Proin neque lacus, semper vel ex at, eleifend rhoncus est.
Cras non nisi urna. Sed feugiat dignissim erat, eget convallis nisl blandit a.
Nullam fringilla diam eget dui placerat fermentum. Maecenas malesuada viverra leo eu bibendum. Nam vulputate enim velit, eu pretium justo tristique ac.
Nam vitae varius augue. Nam pharetra facilisis elementum. Sed nisl risus, vestibulum ut velit at, dapibus sagittis arcu.
Nullam sed dolor suscipit, ef
